Protalix BioTherapeutics, Inc. (PLX) Financial Analysis & Valuation | Quarter Chart
Protalix BioTherapeutics, Inc. (PLX)
PLXPrice: $2.36
Fair Value: 🔒
🔒score
Description
Shares
| Market Cap | $190.15M | Exchange | AMEX |
| Sector | — | Industry | — |
| Country | — | CEO | Dror Bashan |
| IPO Date | 1998-05-15 | CAGR | — |
| Employees | 213 | Website | — |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
PLX chart loading...
Fundamentals
Technicals
| Enterprise Value | $204.41M | P/E Ratio | -29.5 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 131478.21 | P/B Ratio | 131478.21 |
| P/CF Ratio | -2079734.23 | P/FCF Ratio | -1881575.59 |
| EPS | $-0.08 | EPS Growth 1Y | -150.61% |
| EPS Growth 3Y | -118.53% | EPS Growth 5Y | -145.92% |
| Revenue Growth 1Y | 35.42% | Gross Margin | 0.42% |
| Operating Margin | 0.1% | Profit Margin | 0.09% |
| ROE | 0.1% | ROA | 0.07% |
| ROCE | 0.11% | Current Ratio | 3.03 |
| Quick Ratio | 2.06 | Cash Ratio | 0.62 |
| Debt/Equity | 0.11 | Interest Coverage | 8.01 |
| Altman Z Score | 16.89 | Piotroski Score | 4 |